NO992260L - Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi - Google Patents

Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi

Info

Publication number
NO992260L
NO992260L NO992260A NO992260A NO992260L NO 992260 L NO992260 L NO 992260L NO 992260 A NO992260 A NO 992260A NO 992260 A NO992260 A NO 992260A NO 992260 L NO992260 L NO 992260L
Authority
NO
Norway
Prior art keywords
bicistronadenovirus
dyslipoproteinemia
recombinant
treatment
conditions associated
Prior art date
Application number
NO992260A
Other languages
English (en)
Other versions
NO992260D0 (no
Inventor
Patrick Benoit
Nicolas Duverger
Didier Rouy
Sandrine Seguret
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO992260D0 publication Critical patent/NO992260D0/no
Publication of NO992260L publication Critical patent/NO992260L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/1029Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • C12N9/20Triglyceride splitting, e.g. by means of lipase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO992260A 1996-11-15 1999-05-10 Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi NO992260L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9613969A FR2755975B1 (fr) 1996-11-15 1996-11-15 Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
PCT/FR1997/002043 WO1998022606A1 (fr) 1996-11-15 1997-11-13 Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies

Publications (2)

Publication Number Publication Date
NO992260D0 NO992260D0 (no) 1999-05-10
NO992260L true NO992260L (no) 1999-05-10

Family

ID=9497670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992260A NO992260L (no) 1996-11-15 1999-05-10 Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi

Country Status (14)

Country Link
EP (1) EP0941355A1 (no)
JP (1) JP2001506488A (no)
KR (1) KR20000053320A (no)
AU (1) AU721654B2 (no)
BR (1) BR9712957A (no)
CA (1) CA2271437A1 (no)
CZ (1) CZ170399A3 (no)
FR (1) FR2755975B1 (no)
HU (1) HUP9904500A3 (no)
IL (1) IL129823A0 (no)
NO (1) NO992260L (no)
SK (1) SK63499A3 (no)
WO (1) WO1998022606A1 (no)
ZA (1) ZA9710271B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047690A2 (en) * 1998-03-16 1999-09-23 Introgen Therapeutics, Inc. Multigene vectors
DE10039844A1 (de) * 1999-08-10 2001-04-19 Hepavec Ag Fuer Gentherapie Kombinationsvektoren für den Gentransfer, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
CA2404235C (en) * 2000-03-24 2010-09-21 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7208322B2 (en) 2001-04-02 2007-04-24 Agilent Technologies, Inc. Sensor surfaces for detecting analytes
US9976171B2 (en) * 2011-08-08 2018-05-22 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
WO2021031551A1 (zh) 2019-08-19 2021-02-25 南京诺惟生物科技有限公司 一种调控脂质代谢的复制型溶瘤腺病毒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003143A1 (en) * 1991-08-07 1993-02-18 Anderson W French Retroviral vectors containing internal ribosome entry sites
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
PT787200E (pt) * 1994-10-28 2005-08-31 Univ Pennsylvania Adenovirus melhorado e metodos para a sua utilizacao
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

Also Published As

Publication number Publication date
BR9712957A (pt) 2000-02-01
HUP9904500A3 (en) 2002-01-28
FR2755975B1 (fr) 1999-05-07
WO1998022606A1 (fr) 1998-05-28
CA2271437A1 (fr) 1998-05-28
AU721654B2 (en) 2000-07-13
NO992260D0 (no) 1999-05-10
AU5125298A (en) 1998-06-10
ZA9710271B (en) 1998-08-21
KR20000053320A (ko) 2000-08-25
JP2001506488A (ja) 2001-05-22
SK63499A3 (en) 2000-05-16
IL129823A0 (en) 2000-02-29
FR2755975A1 (fr) 1998-05-22
CZ170399A3 (cs) 1999-08-11
HUP9904500A2 (hu) 2000-05-28
EP0941355A1 (fr) 1999-09-15

Similar Documents

Publication Publication Date Title
PT936908E (pt) Derivados anticonvulsivos uteis no tratamento de esclerose lateral amiotrofica (ela)
NO20005864D0 (no) Quinasoler til behandling av hjernesvulst
FI971568A (fi) Menetelmä resistenttien kasvainten hoitamiseksi
NO20005884L (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
DK0752870T3 (da) Anvendelse af Mycobacterium til behandling af tumorer
NO991459D0 (no) Anvendelse av 1-hydroksy-2-pyridoner til behandling av hudinfeksjoner
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
NO992260D0 (no) Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi
FI962420A0 (fi) Foerstaerkare med laogbrus
NO991734D0 (no) Pyrazolinoner for behandling av potensforstyrrelser
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
NO991158L (no) FremgangsmÕte for behandling av amyotrofisk lateralsklerose
NO920983D0 (no) Fremgangsmaate for behandling av nevrodegenerative tilstander
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer
IT1281294B1 (it) Gioiello e procedimento per la realizzazione dello stesso.
IT1277048B1 (it) Procedimento per la preparazione di cefalosporine attraverso ciclizzazione riduttiva dicarbonilica per trattamento con
NO962812D0 (no) Fremgangsmåte for behandling av nervebetennelse
NO996166L (no) FremgangsmÕte for behandling av avluter
UA25833C2 (uk) Засіб для лікуваhhя мелаhомобластом
FI1370U1 (fi) Bordsskiva foer bord med belaeggning av massivt trae
ITMI940806A0 (it) Procedimento per la prevenzione della nebbia lungo le strade
KR970063634U (ko) 정착 램프의 과열 방지 장치
FI961548A0 (fi) Diskborste med elektrisk drift